AR042530A1 - Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18 - Google Patents

Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18

Info

Publication number
AR042530A1
AR042530A1 ARP030104709A ARP030104709A AR042530A1 AR 042530 A1 AR042530 A1 AR 042530A1 AR P030104709 A ARP030104709 A AR P030104709A AR P030104709 A ARP030104709 A AR P030104709A AR 042530 A1 AR042530 A1 AR 042530A1
Authority
AR
Argentina
Prior art keywords
vaccine
viroid particles
papiloma virus
human papiloma
viroid
Prior art date
Application number
ARP030104709A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR042530A1 publication Critical patent/AR042530A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP030104709A 2002-12-20 2003-12-18 Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18 AR042530A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
AR042530A1 true AR042530A1 (es) 2005-06-22

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104709A AR042530A1 (es) 2002-12-20 2003-12-18 Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18

Country Status (28)

Country Link
US (2) US20060251676A1 (OSRAM)
EP (1) EP1572233B1 (OSRAM)
JP (1) JP5475939B2 (OSRAM)
KR (3) KR101361769B1 (OSRAM)
AP (1) AP2005003347A0 (OSRAM)
AR (1) AR042530A1 (OSRAM)
AT (1) ATE503492T1 (OSRAM)
AU (1) AU2003293942B2 (OSRAM)
BE (3) BE2015C067I2 (OSRAM)
BR (1) BR0317544A (OSRAM)
CA (1) CA2510457C (OSRAM)
CY (1) CY1111552T1 (OSRAM)
DE (1) DE60336581D1 (OSRAM)
DK (1) DK1572233T3 (OSRAM)
EA (2) EA009179B1 (OSRAM)
EC (1) ECSP055869A (OSRAM)
IL (1) IL169085A (OSRAM)
IS (1) IS2811B (OSRAM)
MA (1) MA27581A1 (OSRAM)
MX (1) MXPA05006764A (OSRAM)
MY (1) MY144492A (OSRAM)
NO (1) NO20052846L (OSRAM)
NZ (1) NZ540811A (OSRAM)
OA (1) OA13147A (OSRAM)
PL (1) PL215257B1 (OSRAM)
PT (1) PT1572233E (OSRAM)
TW (1) TWI349557B (OSRAM)
WO (1) WO2004056389A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666060A1 (en) * 1998-10-16 2006-06-07 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AU2006239471A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
EA013326B1 (ru) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2016065281A1 (en) 2014-10-24 2016-04-28 Tim Ioannides Cancer and skin lesion treatment
RU2721417C2 (ru) * 2015-06-02 2020-05-19 Терумо Кабусики Кайся Адъювантная композиция, содержащая алюминий, и содержащая ее вакцинная композиция
WO2019173465A1 (en) * 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
JP7265563B2 (ja) * 2018-06-04 2023-04-26 シアメン ユニバーシティ ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DE69835294T2 (de) 1997-09-05 2007-07-26 Medimmune, Inc. Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
DK1150712T3 (da) * 1999-02-05 2009-02-02 Merck & Co Inc Vaccineformuleringer mod human papillomavirus
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus

Also Published As

Publication number Publication date
DK1572233T3 (da) 2011-06-27
AU2003293942B2 (en) 2009-12-10
HK1085378A1 (en) 2006-08-25
IS2811B (is) 2012-11-15
ATE503492T1 (de) 2011-04-15
TW200423957A (en) 2004-11-16
JP5475939B2 (ja) 2014-04-16
MXPA05006764A (es) 2005-09-08
AP2005003347A0 (en) 2005-06-30
KR20120123616A (ko) 2012-11-08
AU2003293942A1 (en) 2004-07-14
US20060251676A1 (en) 2006-11-09
US20050287161A1 (en) 2005-12-29
EP1572233A1 (en) 2005-09-14
DE60336581D1 (de) 2011-05-12
MA27581A1 (fr) 2005-10-03
EA200701633A1 (ru) 2007-12-28
IL169085A0 (en) 2007-07-04
WO2004056389A1 (en) 2004-07-08
IL169085A (en) 2014-04-30
PL377710A1 (pl) 2006-02-06
NZ540811A (en) 2007-03-30
KR20120118087A (ko) 2012-10-25
EP1572233B1 (en) 2011-03-30
JP2006512413A (ja) 2006-04-13
ECSP055869A (es) 2005-09-20
IS7885A (is) 2005-06-09
BR0317544A (pt) 2005-11-22
CA2510457C (en) 2011-12-06
BE2015C069I2 (OSRAM) 2024-08-08
PT1572233E (pt) 2011-06-07
PL215257B1 (pl) 2013-11-29
BE2015C068I2 (OSRAM) 2024-08-08
BE2015C067I2 (OSRAM) 2024-08-08
NO20052846L (no) 2005-07-13
KR20050086924A (ko) 2005-08-30
EA200500834A1 (ru) 2006-02-24
CY1111552T1 (el) 2015-08-05
KR101361769B1 (ko) 2014-02-10
CA2510457A1 (en) 2004-07-08
OA13147A (en) 2006-12-13
EA009179B1 (ru) 2007-12-28
TWI349557B (en) 2011-10-01
MY144492A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
CO5280045A1 (es) Nueva composicion
BR0116470A (pt) éteres de imidazoquinolina substituìdos com uréia
ECSP045300A (es) Antígenos virales
EA200601263A1 (ru) Фосфорсодержащие производные пурина (варианты), лекарственное средство на их основе для воздействия на вирус папилломы человека и на опухолевые клетки (варианты)
BRPI0411900A (pt) compostos antivirais e métodos
AR034294A1 (es) Un articulo absorbente resujetable presujetado
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
ECSP088106A (es) Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
IL180612A (en) Pharmaceuticals containing polysaccharides and their use in the preparation of immune system stimulants
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
BRPI0418103A (pt) extrato aquoso do córtex da canela, uso de um extrato de canela, composição, métodos para o tratamento de um paciente que esteja sofrendo de infecção viral e para desinfetar uma área suspeita de ter sido contaminada com vìrus, filtro, método para produzir um vìrus neutralizado para imunização, vìrus neutralizado, formulação de vacina e, método de imunização contra infecção viral
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
MX2022009964A (es) Vacuna contra hpv.
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
UY26832A1 (es) Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer
EA200602289A1 (ru) Применение иматиниба для лечения нарушений работы печени и вирусных инфекций
PL377557A1 (pl) Zastosowanie rezweratrolu do otrzymywania leku użytecznego w leczeniu infekcji wywołanej wirusem grypy
BRPI0608198A2 (pt) adesivo repelente de insetos usável
WO2006113204A3 (en) Thymidine derivatives for treatmemt of kaposi's sarcoma
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
AR049354A1 (es) VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN

Legal Events

Date Code Title Description
FB Suspension of granting procedure